Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 4/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 7/20 | 0.43 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.39 |
| ▸ | FLT3 | P36888 | 2/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | PIM3 | Q86V86 | 2/20 | 0.39 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | STK10 | O94804 | 1/20 | 0.39 |
| ▸ | YES1 | P07947 | 1/20 | 0.39 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.39 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.39 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.39 |
| ▸ | SLK | Q9H2G2 | 1/20 | 0.39 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.39 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1658386 | 0.90 | GUCY1B2 (0.36) | METNQO2PIM1GUCY1B2GUCY1A2 | |
| SCHEMBL1133917 | 0.87 | MET (0.53) | METNQO2PIM1PDE3BPDE3A | |
| SCHEMBL1658272 | 0.87 | GPR119 (0.45) | PIM1 | |
| SCHEMBL1133713 | 0.86 | GUCY1B2 (0.35) | METNQO2PIM1GUCY1B2GUCY1A2 | |
| SCHEMBL1133840 | 0.83 | PIM1 (0.43) | METNQO2PIM1PDE3BPDE3A | |
| SCHEMBL1133888 | 0.78 | CYP1A2 (0.43) | METNQO2PIM1FLT3PDE3B | |
| SCHEMBL1133887 | 0.78 | CYP1A2 (0.43) | METNQO2PIM1PDE3BPDE3A | |
| SCHEMBL31495102 | 0.75 | MET (0.53) | METNQO2CXCR1ACHE | |
| SCHEMBL13449240 | 0.75 | MET (0.53) | METNQO2CXCR1ACHE | |
| SCHEMBL23344096 | 0.74 | MET (0.48) | METNQO2PIM1PIM2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497266-B2 | 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | claimed |
| US-8497266-B2 | 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| EP-2285811-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-Ý1,2,4¨TRIAZOLOÝ4,3-B¨PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | RET, ERBB2, MET | MET 3/4885NQO2 1615/4885PIM1 73/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.